Form 4: CVS Health Executive Reports Stock Transactions

CVS Health executive Tilak Mandadi reported transactions involving restricted stock units and stock options, reflecting changes in beneficial ownership.

Summary

• Tilak Mandadi, EVP, Chief Exp & Tech Officer at CVS Health Corp, reported transactions on March 31, 2026, and April 1, 2026.
• On March 31, 2026, 22,277 restricted stock units (RSUs) were acquired at a price of $71.82, increasing beneficial ownership to 88,543 shares.
• On April 1, 2026, 3,634 shares of common stock were disposed of at $72.49 per share, reducing beneficial ownership to 79,684 shares.
• A stock option for 143,712 shares was granted on March 31, 2026, with an exercise price of $71.82, becoming exercisable in three equal annual installments starting March 31, 2027, and expiring March 31, 2036.
• The disposal of shares on April 1, 2026, was to cover withholding taxes due upon the vesting and settlement of RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine executive stock transactions and compensation-related events rather than significant strategic shifts or financial performance indicators.

Positives

• Acquisition of 22,277 restricted stock units, indicating continued equity-based compensation and potential future value.
• Grant of a stock option for 143,712 shares, aligning executive interests with long-term company performance.

Negatives

• Disposal of 3,634 shares of common stock to cover tax obligations, representing a reduction in direct shareholding.

Future Outlook

The stock option granted on March 31, 2026, becomes exercisable in three equal annual installments starting March 31, 2027, and expires on March 31, 2036. Restrictions on the awarded RSUs also lapse in three equal installments, commencing March 31, 2027.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for executives and directors to report changes in their beneficial ownership of company stock, providing transparency to the market regarding insider transactions.

Stakeholder Impact

• Shareholders: Increased transparency into executive equity holdings and compensation structures.
• Employees: The transactions reflect the company's use of equity-based compensation, which can influence employee motivation and retention.
• Management: The transactions are part of standard executive compensation and equity management practices.

Next Steps

• Vesting and settlement of restricted stock units in three equal installments starting March 31, 2027.
• Exercisability of stock options in three equal annual installments starting March 31, 2027.

Key Dates

Keywords

CVS Health, Form 4, Stock Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Beneficial Ownership, Insider Trading